BRCA2 and breast carcinoma: Longer use of OC, especially before the first full-term pregnancy, was also associated with an increased risk of breast cancer for both BRCA1 and BRCA2 mutation carriers (HR = 1.49; 95% CI = 1.05–2.11 for BRCA1 subjects and HR = 2.58; 95% CI = 1.21–5.49 for BRCA2 subjects) [113].